Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS-B: Vutrisiran in ATTR Amyloidosis With Cardiomyopathy
NCT04153149Phase 3Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- May 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 33
01
Overview
A Phase 3 trial of vutrisiran in transthyretin amyloidosis (ATTR), sponsored by Alnylam Pharmaceuticals. Started Nov 2019; status: active, not recruiting.
02
Drugs
vutrisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT04153149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153149.